Amendments to the Specification:

Please replace the paragraph beginning at page 62, line 21, with the following rewritten paragraph:

MAb HTF-14 is known to react specifically with a conformational (and non-reduced) epitope on human TF ~~the~~ that maps at or near the TFR binding site. Binding of HTF-14 to TF inhibits TFR binding. The binding of MAb HTF-14 to LDLR/TF chimeric protein constitutes evidence that the TF domain of the chimeric protein is largely intact and suggests that this conformation in LDLR/TF will also have TFR binding activity. Example 12 presents data demonstrating that the LDLR/TF chimeric protein does in fact bind to human TFRs.

Please replace Table 2 on page 68 with the following amended Table 2:

INHIBITOR	0 nM	5 nM	500 nM	500 nM/10 μM $FeCl_3$
None	62,856	-	-	-
holo TF	-	33,602 (53%)	1,026 (2%)	1,160 (2%)
LDLR/TF chimeric protein	-	77,982 (117%)	3,363 (5%)	2,724 (4%)